SARS-CoV-2 IgG-/IgA-antibodies

Description

SARS-CoV-2 IgG-/IgA-antibodies :

ELISA assays are suitable for large-scale screening to identify individuals who may have had contact with the virus, even without the manifestation of clinical symptoms. High-quality serologic assays are important for contact tracing, viral reservoir identification, and epidemiologic studies.

While IgG antibodies indicate persistent or even past infection, IgA antibodies are described as early markers of acute respiratory tract infections.

Test system for the detection of antibodies against SARS-CoV-2 virus by ELISA, manufactured by EUROIMMUN (Germany).

- ELISA for EUROIMMUN Anti-SARS-CoV-2 (IgA and IgG) shows a sensitivity of 89-100%.*

- S1 is a more specific antigen than protein N or S (complete) for serologic detection of SARS-CoV-2 antibodies.*

- The specificity of the EUROIMMUN Anti-SARS-CoV-2 ELISA assay varies depending on the sample panel from 87.5 to 100% for IgA and from 83.5 to 97.5% for IgG.*

- ELISA from EUROIMMUN Anti-SARS-CoV-2 (IgA and IgG) are highly correlated with PRNT results.*

- Detection of IgA antibodies may be of additional value in the diagnosis of SARS-CoV-2 infection at an early stage of disease.*

Both test systems used in the serological diagnosis of COVID-19, PRNT (neutralization reaction-standard serological test) and ELISA, are suitable not only for the diagnosis of SARS-CoV-2 infection, but also for differentiation from infections caused by other pathogens that produce similar symptoms.

EUROIMMUN is one of the first European diagnostic test manufacturers to provide CE-marked antibody detection systems to support COVID-19 diagnostics.

The Anti-SARS-CoV-2 ELISA for immunoglobulin classes A and G from EUROIMMUN, a PerkinElmer, Inc. company (NYSE: PKI), has received CE Mark and can now be used for COVID-19 diagnostics.

Sources:
- The study "SARS-CoV-2 specific antibody responses in COVID-19 patients" was supported by: Zoonoses Anticipation and Preparedness Initiative (ZAPI project ; IMI grant no. 115760) supported by: Zoonoses Anticipation and Preparedness Initiative (ZAPI project ; IMI grant no. 115760), with the help and financial support of IMI and the European Commission, and the contribution of EFPIA partners. March 2020 (medRxiv 2020.03.18.20038059; doi: 10.1101/2020.03.18.20038059; März 2020).
- EUROIMMUN AG, Germany. euroimmun.com